FOOTHILL RANCH, Calif.,
June 3, 2021 /PRNewswire/
-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader
in dental lasers, announced today that recent data published in two
journals, the International Journal of Periodontics &
Restorative Dentistry and Lasers in Medical Science, demonstrates
BIOLASE's Waterlase Er,Cr:YSGG laser technology can be beneficial
for the treatment of peri-implantitis in patients suffering from
the inflammatory disease.
In a first-of-its-kind human histological study led by Dr.
Myron Nevins, researchers reported
that the Er,Cr:YSGG laser has a positive role in debridement of a
titanium implant surface to facilitate subsequent regenerative
treatment. The findings suggest the value that BIOLASE's Waterlase
technology has for dentists who are seeking devices that can assist
in periodontal treatments.
Similarly, data published in Lasers in Medical Science by Drs.
David M. Kim and Dr. Chia-Yu (Jennifer) Chen, displays that the
Er,Cr:YSGG laser effectively decreases bacteria from zirconia
discs. Furthermore, fibroblast attachments on the surfaces of the
zirconia discs show more adherence when treated with Er,Cr:YSGG
laser technology. There is a significant increase in the number of
zirconia dental implants being placed throughout the world.
"Although studies can vary, data suggests as much as 56% of
people with dental implants may have peri-implantitis," said
John Beaver, CEO of BIOLASE.
"Unfortunately, treatment methods for peri-implantitis can be
painful, costly, ineffective and unpredictable. The findings of
these recent studies confirm that Waterlase laser technology can be
a more viable treatment option than alternative methods. We look
forward to continuing to provide dentists with minimally invasive
treatment options through advanced laser technology that benefits
To learn more about BIOLASE's Waterlase laser and other
available laser technologies, visit biolase.com.
About BIOLASE, Inc.
BIOLASE is a medical device company that develops, manufactures,
markets, and sells laser systems in dentistry and medicine.
BIOLASE's products advance the practice of dentistry and medicine
for patients and healthcare professionals. BIOLASE's proprietary
laser products incorporate approximately 271 patented and 40
patent-pending technologies designed to provide biologically and
clinically superior performance with less pain and faster recovery
times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications. BIOLASE has sold over 41,200 laser systems to date in
over 80 countries around the world. Laser products under
development address BIOLASE's core dental market and other adjacent
medical and consumer applications.
For updates and information on Waterlase iPlus®,
Waterlase Express™, and laser dentistry, find BIOLASE online at
www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at
www.twitter.com/biolaseinc, Instagram at
www.instagram.com/waterlase_laserdentistry, and LinkedIn at
BIOLASE®, Waterlase® and Waterlase
iPlus® are registered trademarks of BIOLASE, Inc.
View original content to download
SOURCE BIOLASE, Inc.